Durability of RSV Prefusion F Vaccine Protection across Two RSV Seasons.
Mats C H Lassen, Niklas Dyrby Johansen, Sine H Christensen et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the durability of protection from the RSV prefusion F vaccine (RSVpreF) in adults aged 60 and older across two RSV seasons. The study found that during the second season, the vaccine demonstrated a 56.2% effectiveness against RSV-related hospitalization compared to no vaccine, with an incidence rate of 0.11 events per 1000 person-years in the vaccinated group versus 0.25 in the control group.
Key findings
- Vaccine effectiveness during the second season was 56.2% compared to no vaccine.
- Incidence rate of RSV-related RTD hospitalization was 0.11 events per 1000 person-years in the RSVpreF group.
- Overall vaccine effectiveness across both seasons was 70.6%.
- No significant difference in all-cause respiratory and cardiorespiratory hospitalization outcomes in the second season.
Why it matters
Understanding the durability of vaccine protection against RSV is crucial for managing the health of older adults, who are at higher risk for severe disease. This study provides insights into the ongoing effectiveness of the RSVpreF vaccine over consecutive seasons.